Phase II trial in Japan of PLX PAD in patients with critical limb ischaemia.

Trial Profile

Phase II trial in Japan of PLX PAD in patients with critical limb ischaemia.

Planning
Phase of Trial: Phase I/II

Latest Information Update: 10 May 2016

At a glance

  • Drugs PLX PAD (Primary)
  • Indications Peripheral arterial disorders
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 10 May 2016 According to a Pluristem media release, the company anticipates that data from this trial will lead to conditional marketing approval for PLX-PAD in the treatment of Critical Limb Ischemia in Japan.
    • 10 May 2016 According to Pluristem media release, Japan's Pharmaceuticals and Medical Devices Agency has cleared the protocol for this trial.
    • 21 Dec 2015 According to Pluristem media release, Pluristem expects to submit the formal Clinical Trial Notification (CTN) to the PDMA, based on the agreement reached with the regulatory body, in early 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top